Multiple sclerosis, rituximab, and COVID-19
© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association..
We conducted a retrospective cohort study in Kaiser Permanente Southern California from 1 January 2020 to 30 September 2020. We found that rituximab-treated persons with multiple sclerosis (pwMS, n = 1895) were more likely be hospitalized (n = 8, 33.3%), but not die (n = 0) from COVID-19, compared to the 4.81 million non-MS population (5.8% and 1.4%, respectively). Time in months (adjusted OR = 0.32, 95% CI = 0.15-0.69, p = 0.0033) and receiving 1000 mg compared to lower doses at last infusion (adjusted OR = 6.28, 95% CI = 1.38-28.5, p = 0.0173) were independent predictors of COVID-19 severity. Rituximab-treated pwMS should be counseled to take extra precautions in the 5 months following each infusion. Using extended dosing intervals and lower doses could be considered.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Annals of clinical and translational neurology - 8(2021), 4 vom: 01. Apr., Seite 938-943 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Langer-Gould, Annette [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 26.04.2021 Date Revised 26.04.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/acn3.51342 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323389244 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323389244 | ||
| 003 | DE-627 | ||
| 005 | 20231225184056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/acn3.51342 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1077.xml |
| 035 | |a (DE-627)NLM323389244 | ||
| 035 | |a (NLM)33783140 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Langer-Gould, Annette |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multiple sclerosis, rituximab, and COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.04.2021 | ||
| 500 | |a Date Revised 26.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. | ||
| 520 | |a We conducted a retrospective cohort study in Kaiser Permanente Southern California from 1 January 2020 to 30 September 2020. We found that rituximab-treated persons with multiple sclerosis (pwMS, n = 1895) were more likely be hospitalized (n = 8, 33.3%), but not die (n = 0) from COVID-19, compared to the 4.81 million non-MS population (5.8% and 1.4%, respectively). Time in months (adjusted OR = 0.32, 95% CI = 0.15-0.69, p = 0.0033) and receiving 1000 mg compared to lower doses at last infusion (adjusted OR = 6.28, 95% CI = 1.38-28.5, p = 0.0173) were independent predictors of COVID-19 severity. Rituximab-treated pwMS should be counseled to take extra precautions in the 5 months following each infusion. Using extended dosing intervals and lower doses could be considered | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Smith, Jessica B |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Bonnie H |e verfasserin |4 aut | |
| 700 | 0 | |a KPSC MS Specialist Group |e verfasserin |4 aut | |
| 700 | 1 | |a Beaber, Brandon E |e investigator |4 oth | |
| 700 | 1 | |a Brara, Sonu M |e investigator |4 oth | |
| 700 | 1 | |a Debacker, Julie |e investigator |4 oth | |
| 700 | 1 | |a Nielsen, Allen Scott |e investigator |4 oth | |
| 700 | 1 | |a Amirova, Samira |e investigator |4 oth | |
| 700 | 1 | |a Ayeni, Oluwasheyi |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of clinical and translational neurology |d 2014 |g 8(2021), 4 vom: 01. Apr., Seite 938-943 |w (DE-627)NLM234874031 |x 2328-9503 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2021 |g number:4 |g day:01 |g month:04 |g pages:938-943 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/acn3.51342 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2021 |e 4 |b 01 |c 04 |h 938-943 | ||